Catalent Biologics (formerly Paragon Bioservices Inc.)Read More
Seamlessly adopt new processes and produce higher quality therapeutics faster.
Stay ahead of the rapidly evolving biotech industry with a flexible facility and expertly designed process systems. Readily adapt to new advances while producing the best quality drug products quickly and cost-effectively.
The biotech industry doesn’t just rely on us for engineering, consulting and construction knowledge; biotech leaders come to CRB for expertise in industry trends and technologies.
Push the boundaries of facility design and construction for the future of medicine manufacturing. Work with a team that’s pioneering processes and facilities to produce complex biological products.
Build from nothing, expand your facility or improve your current process. Get a custom, best-in-class solution.
What’s the next step? Tell us more about your project.
What we do:
Cell + Gene Therapy
Human Plasma-Derived Therapeutics
Next generation therapies now.
Achieve a facility that is flexible enough to continuously adopt technology which doesn’t yet exist, resilient enough to support rapid scale-up to commercialization, and advanced enough to keep you at the front of the race toward breakthrough autologous and allogeneic cell and gene therapies.Read More
Improve your plasma fractionation processing with innovative solutions.
Clean, streamline and simplify your bulk processing facility with the right design and regulatory expertise. From process utilities to equipment, get a solution that includes the mixing, liquid transferring and chilling, filtering and clean-in-place considerations needed to maximize your cleanability and efficiency, while minimizing operator intervention. No matter the extent of your project, our team builds value into your human plasma-derived therapeutics facility by finding the best opportunities to improve your outcomes while ensuring compliance to applicable codes.
Introducing Horizons, a new CRB insights series exploring key trends across the life sciences.
Our new report explores how cell and gene therapy companies are meeting the obstacles and opportunities of a world on defense against disease.